Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
08.08.2024 12:21:35

Haemonetics Q1 Profit Slips, Despite Revenue Growth, Reaffirms FY25 Adj. EPS, Revenue Range

(RTTNews) - Haemonetics Corp. (HAE) Thursday announced a 6.5 percent decline in first quarter earnings, despite an 8 percent increase in revenue, compared to the prior year.

The quarterly earnings were $38.37 million or $0.74 per share, down from $41.04 million or $0.80 per share last year. On an adjusted basis, earnings were $1.02 per share.

The amortization of fair value inventory step-up related to the Attune Medical acquisition, restructuring costs, and higher Operating expenses impacted the decline of profit.

On average, 7 analysts polled by Thomson Reuters expected the company to earn $1 per share. Analysts estimte usually exclude special items.

Revenue for the first quarter came in to $336.17 million, from $311.33 million a year ago. Wall Street were looking for $335.38 million.

Looking ahead to the fiscal 2025, the company reaffirmed adjusted earnings per share guidance in a range of $4.45-$4.75 per share. Total revenue guidance is affirmed in a range of 5-8 percent. Analysts expect the fiscal earnings of $4.6 per share on revenue of $1.4 billion.

Analysen zu Haemonetics Corp.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Haemonetics Corp. 81,00 0,62% Haemonetics Corp.